|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 May 2001, Vol. 97, No. 10, pp. 3210-3217
NEOPLASIA
Identification of a leukemic counterpart of the plasmacytoid
dendritic cells
Laurence Chaperot,
Nathalie Bendriss,
Olivier Manches,
Rémy Gressin,
Marc Maynadie,
Franck Trimoreau,
Hubert Orfeuvre,
Bernadette Corront,
Jean Feuillard,
Jean-Jacques Sotto,
Jean-Claude Bensa,
Francine Brière,
Joël Plumas, and
Marie-Christine Jacob
From the Department of Research and Development,
Research Group on Lymphoma, EFS Rhône-Alpes Grenoble, La Tronche,
France; Schering Plough Laboratory for Immunological Research,
Dardilly, France; Groupe d'Etudes Immunologique des Leucémies,
Immunology Laboratory, Medicine Faculty, Vandoeuvre Les Nancy, France;
Clinical Hematological Department, Research Group on Lymphoma,
Michallon Hospital, Grenoble, France; Hematological Department, Dijon
Hospital, Dijon, France; Cellular Hematological Department, Dupuytren
Hospital, Limoges, France; Oncology Department, Bourg en Bresse
Hospital, Bourg en Bresse, France; Hematological Department, Annecy
Hospital, Annecy, France; and Hematological Department, Avicenne
Hospital, Bobigny, France.
This work aims to demonstrate that
CD4+CD56+ malignancies arise from transformed
cells of the lymphoid-related plasmacytoid dendritic cell (pDC) subset.
The analysis of malignant cells from 7 patients shows that in all
cases, like pDCs, leukemic cells are negative for lineage markers CD3,
CD19, CD13, CD33, and CD11c but express high levels of interleukin-3
receptor  chain (IL-3R), HLA-DR, and CD45RA. Tumor cells produce
interferon- in response to influenza virus, while upon maturation
with IL-3 they become a powerful inducer of naive CD4+
T-cell proliferation and promote their T-helper 2 polarization. As
pDCs, leukemic cells also express pre-T and lambda-like 14.1 transcripts, arguing in favor of a lymphoid origin. In addition, malignant cells express significant levels of CD56 and granzyme B. Overall, those observations suggest that
CD4+CD56+ leukemic cells could represent the
malignant counterpart of pDCs, both of which are closely related to B,
T, and NK cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al.
Novel markers of normal and neoplastic human plasmacytoid dendritic cells
Blood,
April 1, 2008;
111(7):
3778 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C.-S. Hu, K.-B. Tsai, G.-S. Chen, and P.-H. Chen
Infantile CD4+/CD56+ hematodermic neoplasm
Haematologica,
September 1, 2007;
92(9):
e91 - e93.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dijkman, R. van Doorn, K. Szuhai, R. Willemze, M. H. Vermeer, and C. P. Tensen
Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities
Blood,
February 15, 2007;
109(4):
1720 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Vremec, M. O'Keeffe, H. Hochrein, M. Fuchsberger, I. Caminschi, M. Lahoud, and K. Shortman
Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells
Blood,
February 1, 2007;
109(3):
1165 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Allman, M. Dalod, C. Asselin-Paturel, T. Delale, S. H. Robbins, G. Trinchieri, C. A. Biron, P. Kastner, and S. Chan
Ikaros is required for plasmacytoid dendritic cell differentiation
Blood,
December 15, 2006;
108(13):
4025 - 4034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Chapiro, E. Delabesse, V. Asnafi, C. Millien, F. Davi, E. Nugent, K. Beldjord, T. Haferlach, D. Grimwade, and E. A. Macintyre
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17)
Blood,
November 15, 2006;
108(10):
3484 - 3493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chaperot, A. Blum, O. Manches, G. Lui, J. Angel, J.-P. Molens, and J. Plumas
Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells
J. Immunol.,
January 1, 2006;
176(1):
248 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-W. Lin, T.-Y. Liu, S.-U. Chen, K.-T. Wang, L. J. Medeiros, and S.-M. Hsu
CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features
Blood,
November 15, 2005;
106(10):
3567 - 3574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bendriss-Vermare, S. Burg, H. Kanzler, L. Chaperot, T. Duhen, O. de Bouteiller, M. D'agostini, J.-M. Bridon, I. Durand, J. M. Sederstrom, et al.
Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production
J. Leukoc. Biol.,
October 1, 2005;
78(4):
954 - 966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fuchs, M. Cella, T. Kondo, and M. Colonna
Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44
Blood,
September 15, 2005;
106(6):
2076 - 2082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Drenou, L. Amiot, N. Setterblad, S. Taque, V. Guilloux, D. Charron, R. Fauchet, and N. Mooney
MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells
J. Leukoc. Biol.,
April 1, 2005;
77(4):
560 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jahrsdorfer, L. Muhlenhoff, S. E. Blackwell, M. Wagner, H. Poeck, E. Hartmann, R. Jox, T. Giese, B. Emmerich, S. Endres, et al.
B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides
Clin. Cancer Res.,
February 15, 2005;
11(4):
1490 - 1499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Garnache-Ottou, L. Chaperot, S. Biichle, C. Ferrand, J.-P. Remy-Martin, E. Deconinck, P. D. de Tailly, B. Bulabois, J. Poulet, E. Kuhlein, et al.
Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells
Blood,
February 1, 2005;
105(3):
1256 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. McKenna, A.-S. Beignon, and N. Bhardwaj
Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity
J. Virol.,
January 1, 2005;
79(1):
17 - 27.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Bekkenk, P. M. Jansen, C. J. L. M. Meijer, and R. Willemze
CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature
Ann. Onc.,
July 1, 2004;
15(7):
1097 - 1108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
CD56+ Lymphoma With Skin Involvement: Clinicopathologic Features and Classification
Arch Dermatol,
April 1, 2004;
140(4):
427 - 436.
|
|
|
|
|
|
|
B. Vanbervliet, N. Bendriss-Vermare, C. Massacrier, B. Homey, O. de Bouteiller, F. Briere, G. Trinchieri, and C. Caux
The Inducible CXCR3 Ligands Control Plasmacytoid Dendritic Cell Responsiveness to the Constitutive Chemokine Stromal Cell-derived Factor 1 (SDF-1)/CXCL12
J. Exp. Med.,
September 2, 2003;
198(5):
823 - 830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herling, M. A. Teitell, R. R. Shen, L. J. Medeiros, and D. Jones
TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin
Blood,
June 15, 2003;
101(12):
5007 - 5009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Asnafi, K. Beldjord, E. Boulanger, B. Comba, P. Le Tutour, M.-H. Estienne, F. Davi, J. Landman-Parker, P. Quartier, A. Buzyn, et al.
Analysis of TCR, pTalpha , and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment
Blood,
April 1, 2003;
101(7):
2693 - 2703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Comeau, A.-R. Van der Vuurst de Vries, C. R. Maliszewski, and L. Galibert
CD123bright Plasmacytoid Predendritic Cells: Progenitors Undergoing Cell Fate Conversion?
J. Immunol.,
July 1, 2002;
169(1):
75 - 83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Leroux, F. Mugneret, M. Callanan, I. Radford-Weiss, N. Dastugue, J. Feuillard, F. Le Mee, G. Plessis, P. Talmant, N. Gachard, et al.
CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique
Blood,
May 13, 2002;
99(11):
4154 - 4159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Feuillard, M.-C. Jacob, F. Valensi, M. Maynadie, R. Gressin, L. Chaperot, C. Arnoulet, F. Brignole-Baudouin, B. Drenou, E. Duchayne, et al.
Clinical and biologic features of CD4+CD56+ malignancies
Blood,
March 1, 2002;
99(5):
1556 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
